Better Targeting, Delivery of RNAi Therapies
Systems Biology Opens New Research Pathways
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Takeda/Lilly’s $9B Actos Verdict
A Louisiana jury this week awarded a staggering $9 billion in punitive damages to the companies behind Actos (Pioglitazone HCl). Takeda Pharmaceutical and its partner from 1999–2006, Eli Lilly, have promised to appeal the decision, which came after the jury decided in favor of plaintiff Terrence Allen of Attica, N.Y., who blamed Actos for causing his bladder cancer after taking the drug for five years. The jury’s decision came in part after hearing that Takeda lost or destroyed documents compiled by 46 current and former employees and sales representatives involved in marketing Actos.